Christine L Kempton

Summary

Affiliation: Emory University
Country: USA

Publications

  1. ncbi request reprint Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA, USA
    J Thromb Haemost 4:2576-81. 2006
  2. ncbi request reprint Novel therapeutic agents in the management of hemorrhage and thrombosis
    Christine L Kempton
    Aflac Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Cardiovasc Hematol Agents Med Chem 4:319-34. 2006
  3. pmc Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A
    Christine L Kempton
    Emory University, Atlanta, Georgia 30322, USA
    Am J Hematol 87:933-6. 2012
  4. pmc Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein
    Ryan J Summers
    Emory University School of Medicine, Atlanta, GA, USA
    Blood 117:3190-8. 2011
  5. doi request reprint Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma
    Fania Szlam
    Department of Anesthesiology, Emory University School of Medicine, 1364 Clifton Rd, NE, Atlanta, GA 30322, USA
    Anesth Analg 106:719-24, table of contents. 2008
  6. doi request reprint How we treat a hemophilia A patient with a factor VIII inhibitor
    Christine L Kempton
    Aflac Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Blood 113:11-7. 2009
  7. ncbi request reprint Hemophilia care in the 21st century
    Christine L Kempton
    Division of Hematology Oncology at the University of North Carolina, Chapell Hill, NC 27599 7035, USA
    Clin Adv Hematol Oncol 2:733-40. 2004
  8. ncbi request reprint Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations
    Christine L Kempton
    University of North Carolina, Chapel Hill, NC 27599 7035, USA
    Arterioscler Thromb Vasc Biol 25:861-6. 2005

Detail Information

Publications8

  1. ncbi request reprint Incidence of inhibitors in a cohort of 838 males with hemophilia A previously treated with factor VIII concentrates
    C L Kempton
    Aflac Cancer Center and Blood Disorders Service, Emory University, Atlanta, GA, USA
    J Thromb Haemost 4:2576-81. 2006
    ..Understanding the baseline rate of inhibitor development in the population of previously treated patients (PTPs) is important when evaluating the effect of exposure to new factor replacement products on inhibitor formation...
  2. ncbi request reprint Novel therapeutic agents in the management of hemorrhage and thrombosis
    Christine L Kempton
    Aflac Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA, USA
    Cardiovasc Hematol Agents Med Chem 4:319-34. 2006
    ..These agents and others will be discussed in detail with respect to mechanism of action, clinical efficacy and safety...
  3. pmc Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia A
    Christine L Kempton
    Emory University, Atlanta, Georgia 30322, USA
    Am J Hematol 87:933-6. 2012
    ..4 (95% CI = 1.06–20.03) and 10.21 (95% CI = 1.17–78.28), respectively], whereas ITI alone (n = 9) was not [HR = 1.35 (95% CI = 0.44–4.07)]...
  4. pmc Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein
    Ryan J Summers
    Emory University School of Medicine, Atlanta, GA, USA
    Blood 117:3190-8. 2011
    ....
  5. doi request reprint Antithrombin affects hemostatic response to recombinant activated factor VII in factor VIII deficient plasma
    Fania Szlam
    Department of Anesthesiology, Emory University School of Medicine, 1364 Clifton Rd, NE, Atlanta, GA 30322, USA
    Anesth Analg 106:719-24, table of contents. 2008
    ..We hypothesize that reduced AT concentrations would increase the procoagulant effects of rFVIIa in FVIII-deficient plasma...
  6. doi request reprint How we treat a hemophilia A patient with a factor VIII inhibitor
    Christine L Kempton
    Aflac Cancer Center and Blood Disorders Service and Winship Cancer Institute, Emory University, Atlanta, GA 30322, USA
    Blood 113:11-7. 2009
    ..Ideally, prediction and ultimately prevention will come with an improved understanding of how patient-specific and treatment-related factors work together to influence anti-factor VIII antibody production...
  7. ncbi request reprint Hemophilia care in the 21st century
    Christine L Kempton
    Division of Hematology Oncology at the University of North Carolina, Chapell Hill, NC 27599 7035, USA
    Clin Adv Hematol Oncol 2:733-40. 2004
  8. ncbi request reprint Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations
    Christine L Kempton
    University of North Carolina, Chapel Hill, NC 27599 7035, USA
    Arterioscler Thromb Vasc Biol 25:861-6. 2005
    ....